home / stock / abvc / abvc news


ABVC News and Press, ABVC BioPharma Inc. From 03/14/23

Stock Information

Company Name: ABVC BioPharma Inc.
Stock Symbol: ABVC
Market: NASDAQ
Website: abvcpharma.com

Menu

ABVC ABVC Quote ABVC Short ABVC News ABVC Articles ABVC Message Board
Get ABVC Alerts

News, Short Squeeze, Breakout and More Instantly...

ABVC - ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare PR Newswire FREMONT, Calif. , March 14, 2023 /PRNewswire/ -- ABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), a clinic...

ABVC - ABVC BioPharma Provides 2023 Pipeline Update

FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device develop...

ABVC - ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross...

ABVC - ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus (R)

Fremont, CA - ( NewMediaWire ) - February 21, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that approval to initiate the Phase II study of its Vitargus® ...

ABVC - ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

FREMONT, CA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that approval to initiate the Phase II study ...

ABVC - ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

Fremont, CA - ( NewMediaWire ) - January 19, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University ...

ABVC - How to Find Cheap Penny Stocks to Make Money Trading 

3 Tips for Finding Cheap Penny Stocks Right Now Penny stocks can be a tempting investment opportunity for traders due to their low price point and the potential for large returns. While penny stocks come with a higher level of risk compared to larger, more established stocks, they also of...

ABVC - 5 Hot Penny Stocks Exploding After News This Week

Red Hot Penny Stocks Moving Higher After Headlines One of the go-to strategies for finding penny stocks to buy – at least for some traders – is identifying obvious catalysts. One of the most “obvious” typically comes in the form of company news. It takes more dilig...

ABVC - FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology today announced that the US Food & Drug Administration n...

ABVC - ABVC BioPharma GAAP EPS of -$0.11 beats by $0.09, revenue of $0.04M beats by $0.01M

ABVC BioPharma press release ( NASDAQ: ABVC ): Q3 GAAP EPS of -$0.11 beats by $0.09 . Revenue of $0.04M (-55.6% Y/Y) beats by $0.01M . For further details see: ABVC BioPharma GAAP EPS of -$0.11 beats by $0.09, revenue of $0.04M beats by $0.01M

Previous 10 Next 10